Skip to main content
. 2022 Jan 20;20(7):1534–1541.e4. doi: 10.1016/j.cgh.2022.01.012

Table 2.

Univariable and Multivariable Analysis on Factors Associated With Positive Serology to BNT162b2 Vaccine in LT Recipients According to Antibody Titers 3 Months After 2-dose Vaccination (Dependent Variable: Positive Serology)

Characteristics Univariable, OR (95% CI) P value Multivariable, OR (95% CI) P value
Age, y (continuous) 0.98 (0.95–0.99) .016
 <40 Ref Ref
 40–65 0.09 (0.01–0.66) .018 0.12 (0.02–0.99) .049
 >65 0.09 (0.01–0.72) .022 0.11 (0.01–0.86) .036
Male sex 0.86 (0.52–1.43) .568
BMI, kg/m2 (continuous) 1.03 (0.97–1.08) .307
 <25 ref
 25–30 0.93 (0.57–1.49) .755
 ≥30 1.35 (0.71–2.56) .36
Smoke history, yes 0.64 (0.39–1.04) .069
Indication to LT
 HCC 192 (39.02) .014 0.77 (0.46–1.28) .327
 Advanced chronic liver disease 300 (60.98) .014 Omitteda
Etiology of liver disease
 Viral infection 0.88 (0.52–1.48) .634
 ALD 0.88 (0.39–1.96) .762
 NAFLD 0.53 (1.12–2.25) .388
 Autoimmune liver diseases 1.13 (0.36–3.51) .832
 Other 2.10 (0.86–5.13) .102
History of re-transplantation 1.07 (0.29–3.97) .915
History of rejection 0.79 (0.48–1.31) .366
Time from transplantation, y
 <1 Ref Ref
 1–5 2.75 (0.80–9.45) .108 2.33 (0.64–8.43) .195
 5–10 4.05 (1.15–14.29) .03 3.53 (0.93–13.39) .063
 >10 5.73 (1.75–18.75) .004 4.55 (1.24–16.60) .022
Immunosuppressive drugs
 Calcineurin inhibitor 0.98 (0.57–1.70) .964
 Antimetabolite 0.42 (0.27–0.66) < .00 0.51 (0.28–0.93) .029
 mTor inhibitor 0.64 (0.40–1.03) .069
Single drug Ref
Two or more drugs 0.32 (0.20–0.51) < .00 0.58 (0.31–1.03) .082
Steroids 0.66 (0.29–1.50) .322
Comorbidities
 Cardiovascular disease 0.54 (0.31–0.93) .028 0.58 (0.32–1.03) .065
 Diabetes mellitus 0.87 (0.52–1.46) .61
 Active cancer 1.07 (0.29–3.97) .915
 Previous cancer 0.98 (0.52–1.84) .958
 Chronic kidney disease 0.90 (0.45–1.81) .776
 Respiratory disease 0.63 (0.15–2.58) .528
 Two or more comorbidities 0.89 (0.49–1.60) .71

Note: Estimates were derived from multivariable logistic regression models adjusted for all the outcome variables. Only the variables found to be significant in the monovariate analysis were added in the multivariate.

Note: Boldface P values indicate statistical significance.

ALD, Alcoholic liver disease; BMI, body mass index; CI, confidence interval; HCC, hepatocellular carcinoma; LT, liver transplant; NAFLD, nonalcoholic fatty liver disease; OR, odds ratio.

a

Omitted because of collinearity